Beta Bionics, Inc. Revenue
Beta Bionics, Inc. (BBNX) reported Revenue of $32.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $32.01M, a 37.76% increase year-over-year.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $27.63M, a 56.62% increase year-over-year.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $32.12M, a 57.15% increase year-over-year.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $27.25M, a 63.14% increase year-over-year.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $100.25M, a 53.94% increase from fiscal 2024.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $65.12M, a 442.93% increase from fiscal 2023.
- Beta Bionics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $11.99M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $32.01M 10-Q · filed 2026-07-29 | $59.64M 10-Q · filed 2026-07-29 | $91.76M derived: sum of 3 quarters · filed 2026-07-29 | $119.01M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $27.63M 10-Q · filed 2026-04-21 | $59.75M derived: sum of 2 quarters · filed 2026-04-21 | $87.00M derived: sum of 3 quarters · filed 2026-04-21 | $110.24M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $32.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $59.37M derived: sum of 2 quarters · filed 2026-02-24 | $82.61M derived: sum of 3 quarters · filed 2026-07-29 | $100.25M 10-K · filed 2026-02-24 |
| 2025-09-30 | $27.25M 10-Q · filed 2025-10-28 | $50.49M derived: sum of 2 quarters · filed 2026-07-29 | $68.13M 10-Q · filed 2025-10-28 | $88.57M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $23.24M 10-Q · filed 2026-07-29 | $40.88M 10-Q · filed 2026-07-29 | $61.32M derived: sum of 3 quarters · filed 2026-07-29 | $78.02M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $17.64M 10-Q · filed 2026-04-21 | $38.08M derived: sum of 2 quarters · filed 2026-04-21 | $54.78M derived: sum of 3 quarters · filed 2026-04-21 | $69.83M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-12-31 | $20.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $37.15M derived: sum of 2 quarters · filed 2026-02-24 | $52.19M derived: sum of 3 quarters · filed 2026-02-24 | $65.12M 10-K · filed 2026-02-24 |
| 2024-09-30 | $16.70M 10-Q · filed 2025-10-28 | $31.75M derived: sum of 2 quarters · filed 2025-10-28 | $44.68M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $15.05M 10-Q · filed 2025-07-29 | $27.98M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | $12.93M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $11.99M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |